-
European Commission Approves Kalydeco for Infants With CF as Young as Six Months
The European Commission has approved a label extension for Kalydeco, allowing its use in infants with cystic fibrosis as young as 6 months. Read more about the decision here.
How do you feel about this news?
Sorry, there were no replies found.
Log in to reply.